Skip to content
Collaborators Login
  • Home
  • Who We Are
    • About Us
  • What We Do
    • Programs & Services
  • BioIntelligence
  • News
    • Press Releases
    • Publications
    • Events
  • Contact Us

Duvvuri, S., Iredale, P., Belov, V., Guehl, N., Moon, S.-H., & Dhaynaut, M. (2021). Evaluation of M4 Muscarinic Receptor Occupancy by CVL-231 Using [11C]MK-6884 PET in Non-Human Primates.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11342722/

Post navigation

Previous: Duvvuri, S., Iredale, P., Pin, S., Smith, D., Zhang, J., Giugliano, A., & Koole, M. (2024, April). Evaluation of M4 Muscarinic Receptor Occupancy by Emraclidine Using [11C]MK-6884 PET in Healthy Volunteers. 2024 Annual Congress of the Schizphrenia Society.
Next: Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., Hurley, D. J., Potter, W. Z., & Paul, S. M. (1997). Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease. Archives of Neurology, 54(4), 465–473.

Recent Posts

  • Enigma Biomedical – USA Announces Collaboration with Alamar Biosciences to Advance the Field of Diagnostics for Neurodegenerative Diseases
  • Enigma Biomedical USA Announces Formation of Scientific Advisory Board
  • Enigma Biomedical USA and the University of Wisconsin
  • Enigma Biomedical USA, Inc. Announces a Collaboration to Apply Novel 4R PET Imaging Biomarkers to CTE Research

Recent Comments

    Archives

    • February 2026

    Categories

    • PRESS RELEASE

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    308 N. Peters Road Suite #201
    Knoxville, TN 37922

    customercare@enigmabiomedicalgroup.com

    © Copyright 2026 Enigma Biomedical Inc. All Rights Reserved.

    • Home
    • Who We Are
      • About Us
    • What We Do
      • Programs & Services
    • BioIntelligence
    • News
      • Press Releases
      • Publications
      • Events
    • Contact Us